Anti-Infective Pharmaceutical Market in China 2021
The anti-infective pharmaceutical market in China in terms of revenue is set to grow by US$ 6 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 2.8% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for anti-infective pharmaceutical. The China anti-infective pharmaceutical market is segmented on the basis of type. By type, it is categorized into antifungal drugs, cephalosporine, penicillin, quinolone, and others.
The report has profiled some of the key players of the market such as Bayer AG, Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Daiichi Sankyo Company Limited, Merck & Co., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., The United Laboratories International Holdings Limited, Wyeth LLC.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the anti-infective pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: antifungal drugs, cephalosporine, penicillin, quinolone, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China anti-infective pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the anti-infective pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for anti-infective pharmaceutical. The China anti-infective pharmaceutical market is segmented on the basis of type. By type, it is categorized into antifungal drugs, cephalosporine, penicillin, quinolone, and others.
The report has profiled some of the key players of the market such as Bayer AG, Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Daiichi Sankyo Company Limited, Merck & Co., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., The United Laboratories International Holdings Limited, Wyeth LLC.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the anti-infective pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: antifungal drugs, cephalosporine, penicillin, quinolone, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China anti-infective pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the anti-infective pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. ANTI-INFECTIVE PHARMACEUTICAL MARKET BY TYPE
4.1 Antifungal Drugs
4.2 Cephalosporine
4.3 Penicillin
4.4 Quinolone
4.5 Others
5. COMPANY PROFILES
5.1 Bayer AG
5.2 Bristol-Myers Squibb Company
5.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.4 Daiichi Sankyo Company Limited
5.5 Merck & Co.
5.6 Pfizer, Inc.
5.7 Sumitomo Dainippon Pharma Co., Ltd.
5.8 The United Laboratories International Holdings Limited
5.9 Wyeth, LLC
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. ANTI-INFECTIVE PHARMACEUTICAL MARKET BY TYPE
4.1 Antifungal Drugs
4.2 Cephalosporine
4.3 Penicillin
4.4 Quinolone
4.5 Others
5. COMPANY PROFILES
5.1 Bayer AG
5.2 Bristol-Myers Squibb Company
5.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.4 Daiichi Sankyo Company Limited
5.5 Merck & Co.
5.6 Pfizer, Inc.
5.7 Sumitomo Dainippon Pharma Co., Ltd.
5.8 The United Laboratories International Holdings Limited
5.9 Wyeth, LLC
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
